Predicting axillary residual disease after neoadjuvant therapy in breast cancer using baseline MRI and ultrasound
Caroline Malhaire(Université Paris Sciences et Lettres), Frédérique Frouin(Inserm), Vincent Cockenpot(Institut Curie), Youlia Kirova(Institut Curie), Jean‐Yves Pierga(Université Paris Cité), Enora Laas(Institut Curie), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Hervé J. Brisse(Université Paris Sciences et Lettres), Fatine Selhane(Institut Gustave Roussy), Emanuela Romano(Inserm), Toulsie Ramtohul(Université Paris Sciences et Lettres), Ozgun Umay(Université Paris Sciences et Lettres), Fabien Reyal(Université Paris Sciences et Lettres)
Cited by 4
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k